Centre to cap trade margins on non-scheduled cancer drugs to 30% of MRP
Average trade mark-up on these drugs now around 170%, reaching 700% in some cases; intervention to cut prices by up to 70% of MRP, resulting in cumulative annual savings of ₹2,500 crore for patients
Read the full story at source →
Post Comment